Resistance-associated NS5A variants of hepatitis C virus are susceptible to interferon-based therapy

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Itakura, Jun ^a   Kurosaki, Masayuki ^a   Higuchi, Mayu ^a   Takada, Hitomi ^a   Nakakuki, Natsuko ^a   Itakura, Yoshie ^a   Tamaki, Nobuharu ^a   Yasui, Yutaka ^a   Suzuki, Shoko ^a   Tsuchiya, Kaoru ^a   Nakanishi, Hiroyuki ^a   Takahashi, Yuka ^a   Maekawa, Shinya ^b   Enomoto, Nobuyuki ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; VIRUS RNA; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; MALE; NONHUMAN; RELAPSE; SEQUENCE ANALYSIS; AMINO ACID SUBSTITUTION; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEPACIVIRUS; METABOLISM; MISSENSE MUTATION; PROCEDURES;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MALE; MUTATION, MISSENSE; RIBAVIRIN; SIMEPREVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84947461016     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138060     Document Type: Article

References (36)

1. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015 Feb 13; 385(9973):1124-35. doi: 10.1016/S0140-6736(14)62401-6 PMID: 25687730
2. Nookathota M, Mukherjee S. Antiviral therapy for chronic hepatitis C in 2014. Expert Rev Clin Pharmacol. 2014 Jul; 7(4):499-505. doi: 10.1586/17512433.2014.915737 PMID: 24939471
3. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010 Feb; 138(2):447-62. doi: 10.1053/j.gastro.2009.11.055 PMID: 20006612
4. Pawlotsky J-M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology. 2011 May; 53(5):1742-51. doi: 10.1002/hep.24262 PMID: 21374691
5. Recommendations on Treatment of Hepatitis C 2015. Available: http://www.easl.eu/research/ourcontributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015
6. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014 Jun; 59(6):2083-91. doi: 10.1002/hep.27113 PMID: 24604476
7. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15; 370(20):1889-98. doi: 10.1056/NEJMoa1402454 PMID: 24725239
8. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May 22; 370(21):1983-92. doi: 10.1056/NEJMoa1402338 PMID: 24795200
9. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando. Lancet. 2014 Nov 11; 385(9973):1087-97. doi: 10.1016/S0140-6736(14) 61793-1 PMID: 25467560
10. Pawlotsky J-M. NS5A inhibitors in the treatment of hepatitis C. J Hepatol. European Association for the Study of the Liver; 2013; 59(2):375-82. doi: 10.1016/j.jhep.2013.03.030
11. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014 Mar 21; 20(11):2902-12. doi: 10.3748/wjg.v20.i11.2902 PMID: 24659881
12. Kohler JJ, Nettles JH, Amblard F, Hurwitz SJ, Bassit L, Stanton RA, et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infect Drug Resist. 2014 Jan; 7:41-56. doi: 10.2147/IDR.S36247 PMID: 24623983
13. Itakura J, Kurosaki M, Takada H, Nakakuki N, Matsuda S, Gondou K, et al. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to IL28B genotype and are sensitive to interferon-based therapy. Hepatol Res. 2015 Jan 6, In Press. doi: 10.1111/hepr.12474
14. Izumi N. Efficacy of daclatasvir in hepatitis C virus. Expert Rev Anti Infect Ther. 2014 Sep; 12(9):1025-31. doi: 10.1586/14787210.2014.942282 PMID: 25059552
15. Kosaka K, Imamura M, Hayes CN, Abe H, Hiraga N, Yoshimi S, et al. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat. 2015 Feb; 22(2):158-65. doi: 10.1111/jvh.12271 PMID: 24943406
16. Yoshimi S, Imamura M, Murakami E, Hiraga N, Tsuge M, Kawakami Y, et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015 May 8, In Press. doi: 10.1002/jmv.24255
17. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng C-Y, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014 Nov 1; 384(9954):1597-605. doi: 10.1016/S0140-6736(14)61059-X PMID: 25078304
18. Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014 Dec; 44(14):E360-7. doi: 10.1111/hepr.12316 PMID: 24612030
19. Honda M, Shirasaki T, Shimakami T, Sakai A, Horii R, Arai K, et al. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology. 2014 Mar; 59(3):828-38. doi: 10.1002/hep.26788 PMID: 24311440
20. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998 Oct 2; 282(5386):103-7. PMID: 9756471
21. Colombatto P, Ciccorossi P, Maina AM, Civitano L, Oliveri F, Coco B, et al. Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells. Clin Pharmacol Ther. 2008 Aug; 84(2):212-5. doi: 10.1038/clpt.2008.21 PMID: 18388885
22. De Francesco R. Molecular virology of the hepatitis C virus. J Hepatol. 1999 Jan; 31 Suppl 1:47-53. PMID: 10622560
23. Hwang J, Huang L, Cordek DG, Vaughan R, Reynolds SL, Kihara G, et al. Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J Virol. 2010 Dec; 84(24):12480-91. doi: 10.1128/JVI.01319-10 PMID: 20926572
24. Lim PJ, Chatterji U, Cordek D, Sharma SD, Garcia-Rivera JA, Cameron CE, et al. Correlation between NS5A dimerization and hepatitis C virus replication. J Biol Chem. 2012 Aug 31; 287(36):30861-73. doi: 10.1074/jbc.M112.376822 PMID: 22801423
25. Ascher DB, Wielens J, Nero TL, Doughty L, Morton CJ, Parker MW. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Jan; 4:4765. doi: 10.1038/srep04765 PMID: 24755925
26. Ross-Thriepland D, Mankouri J, Harris M. Serine phosphorylation of the hepatitis C virus NS5A protein controls the establishment of replication complexes. J Virol. 2014 Dec 31; 89(6):3123-35. doi: 10.1128/JVI.02995-14 PMID: 25552726
27. Chatterji U, Bobardt M, Tai A, Wood M, Gallay PA. Cyclophilin and NS5A inhibitors, but not other antihepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories. Antimicrob Agents Chemother. 2015 May; 59(5):2496-507. doi: 10.1128/AAC.04958-14 PMID: 25666154
28. Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P, et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog. 2008 Mar; 4 (3):e1000035. doi: 10.1371/journal.ppat.1000035 PMID: 18369481
29. McGivern DR, Masaki T, Williford S, Ingravallo P, Feng Z, Lahser F, et al. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology. 2014 Aug; 147 (2):453-62.e7. doi: 10.1053/j.gastro.2014.04.021 PMID: 24768676
30. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 1997 Apr 14; 230(2):217-27. doi: 10.1006/viro.1997.8493 PMID: 9143277
31. Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB, et al. Hepatitis C virus proteins inhibit C3 complement production. J Virol. 2012 Feb; 86(4):2221-8. doi: 10.1128/JVI.06577-11 PMID: 22171262
32. Wang Y, Li J, Wang X, Ye L, Zhou Y, Thomas RM, et al. Hepatitis C virus impairs TLR3 signaling and inhibits IFN-λ 1 expression in human hepatoma cell line. Innate Immun. 2014 Jan; 20(1):3-11. doi: 10.1177/1753425913478991 PMID: 23529855
33. Kriegs M, Bürckstümmer T, Himmelsbach K, Bruns M, Frelin L, Ahlén G, et al. The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo. J Biol Chem. 2009 Oct 9; 284(41):28343-51. doi: 10.1074/jbc.M109.038877 PMID: 19674968
34. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol. 2009 May; 83(9):4395-403. doi: 10.1128/JVI.02352-08 PMID: 19244328
35. Lambert SM, Langley DR, Garnett JA, Angell R, Hedgethorne K, Meanwell NA, et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci. 2014 Jun; 23(6):723-34. doi: 10.1002/pro.2456 PMID: 24639329
36. Penin F, Brass V, Appel N, Ramboarina S, Montserret R, Ficheux D, et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem. 2004 Sep 24; 279 (39):40835-43. doi: 10.1074/jbc.M404761200 PMID: 15247283